Health Care Equipment & Services

Fresenius SE sees modest share dip, but strong safety, efficacy data and low P/E support long‑term value for investors and patients alike.

Explore the 9/21 innovation‑pharma rally: how new biotech IPOs, AI‑driven discovery, and NMPA reforms fuel sharp gains and hidden risks for investors.

Nasdaq 100 bullish trend, strong earnings & aggressive buybacks—yet antitrust scrutiny and US‑China tensions loom. Dive into insights that sharpen investor strategy.

Centene’s latest earnings show modest revenue growth, stable gross margins, and a focus on PBM expansion and tech‑driven care, balancing growth with profit resilience.

Explore why Straumann Holding AG is a “hidden champion” in dental implants—high margins, AI‑driven tools, and attractive valuation discounts could drive upside, but supply chain, currency, and regulatory risks remain.

DexCom’s AI‑driven CGM solutions empower remote patient monitoring, boosting insurer reimbursement and reducing hospital stays while maintaining top‑tier security.

Fresenius‑mAbxience partners with Sandoz to launch a cost‑saving biosimilar for hemophilia A, boosting global access, cutting prices 15‑25%, and driving payer‑friendly reimbursement.

Abbott Laboratories boosts investor confidence with a dual dividend option and strong device portfolio, driving value‑based care and long‑term shareholder value.

Executive buys 15k+ Cencora shares, showing insider confidence and a decade of solid growth—an inside look at its stock performance and future outlook.

Chinese stock rally on Sept 18: Shanghai & Shenzhen surge on AI‑chip gains, real‑estate boost, and fresh tech listings—key insights and risks for investors.